1. Home
  2. Documents

Antiretroviral Therapy and HIV Drug Resistance Documents

Date Range
Guidance for Developing Status Profiles on Communicable Diseases to Further Progress toward Their Elimination in the Region of the Americas
Guidance for Developing Status Profiles on Communicable Diseases to Further Progress toward Their Elimination in the Region of the Americas
Field guides
Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
Guidelines
Paediatric Abacavir/Lamivudine/Dolutegravir (pALD) Fixed-Dose Combination. Introduction and Rollout Planning Considerations for National Programmes
Paediatric Abacavir/Lamivudine/Dolutegravir (pALD) Fixed-Dose Combination. Introduction and Rollout Planning Considerations for National Programmes
Guidelines
Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy
Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy
Technical and scientific products
Guidelines on long-acting injectable cabotegravir for HIV prevention
Guidelines on long-acting injectable cabotegravir for HIV prevention
Guidelines
HIV drug resistance report 2021
HIV drug resistance report 2021
Technical reports
Clinic-based survey of acquired HIV drug resistance
Clinic-based survey of acquired HIV drug resistance
Technical and scientific products
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
Guidelines
HIV drug resistance strategy, 2021 update
HIV drug resistance strategy, 2021 update
Mandates and Strategies
Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens
Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens
Technical and scientific products
HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis
HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis
Guidelines
WHO HIVResNet HIV drug resistance laboratory operational framework
WHO HIVResNet HIV drug resistance laboratory operational framework
Mandates and Strategies
Guidelines for the implementation of multi-month dispensing of antiretrovirals. Version 1, 23 July 2020
Guidelines for the implementation of multi-month dispensing of antiretrovirals. Version 1, 23 July 2020
Guidelines
cover
Policy Brief: Considerations for introducing new antiretroviral drug formulations for children; 2020 (Sólo en inglés)
Policy briefs
cover
Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV; 2020
Technical and scientific products
cover
Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management; 2020
Technical and scientific products
doc
What people living with HIV need to know about HIV and COVID-19
Frequently asked questions (FAQs)
Consolidated recommendations for prevention, care and treatment of viral hepatitis B and C coinfection in people living with HIV; 2019
Technical and scientific products
cover
Policy brief. Maintaining and improving quality of care within HIV clinical services; July 2019 (Sólo en inglés)
Technical and scientific products
cover
Implementation tool. Providing contraceptive services in the context of HIV treatment programmes; July 2019 (Sólo en inglés)
Technical and scientific products
cover
Policy brief. Update of recommendations on first- and second-line antiretroviral regimens
Technical and scientific products